Pages that link to "Q40362170"
Jump to navigation
Jump to search
The following pages link to Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. (Q40362170):
Displaying 22 items.
- Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. (Q33482818) (← links)
- Up-regulation of p21 and TNF-α is mediated in lycorine-induced death of HL-60 cells (Q33648570) (← links)
- Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. (Q33747277) (← links)
- Treatment of lycorine on SCID mice model with human APL cells (Q34576830) (← links)
- Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma (Q36407085) (← links)
- Proteasome inhibition as novel treatment strategy in leukaemia (Q36513273) (← links)
- Redox control of leukemia: from molecular mechanisms to therapeutic opportunities (Q36646486) (← links)
- Therapeutic targets in chronic myeloid leukaemia (Q36794538) (← links)
- An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies (Q37029273) (← links)
- The therapeutic potential of the proteasome in leukaemia (Q37103852) (← links)
- Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines (Q37400663) (← links)
- Critical molecular pathways in cancer stem cells of chronic myeloid leukemia (Q37767357) (← links)
- Hif-1α and Hif-2α synergize to suppress AML development but are dispensable for disease maintenance (Q38813967) (← links)
- Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines (Q39510395) (← links)
- In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines (Q39631346) (← links)
- MMPT: a thiazolidin compound inhibits the growth of lung cancer H1792 cells via Fas-mediated and caspase-dependent apoptosis pathway (Q39856229) (← links)
- Bortezomib has little ex vivo activity in chronic myeloid leukemia: individual tumor response testing comparative study in acute and chronic myeloid leukemia. (Q42144259) (← links)
- WITHDRAWN: Evidence for the critical roles of NF-κB p65 and specificity proteins in the apoptosis-inducing activity of proteasome inhibitors in leukemia cells (Q42176007) (← links)
- Evidence for the Critical Roles of NF-κB p65 and Specificity Proteins in the Apoptosis-Inducing Activity of Proteasome Inhibitors in Leukemia Cells (Q45784186) (← links)
- Proteasome inhibition drastically but reversibly impairs murine lymphocyte development (Q46813398) (← links)
- (Immuno)proteasomes as therapeutic target in acute leukemia (Q47131929) (← links)
- Leukemia stem cells. (Q53293069) (← links)